Prior to last week's FDA decision to reject Lykos Therapeutics' proposed MDMA-assisted therapy for PTSD, Rep. Jack Bergman (R-MI) reflected on the urgent need for better PTSD treatments to reduce veteran suicides and the game plan for lawmakers to keep support for psychedelic-assisted therapies moving forward.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
The MAPS nonprofit remains the largest shareholder, but gives up controlling interest in MAPS PBC, as the for-profit company that seeks to commercialize MDMA therapy successfully attracts investors.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
We encourage you to read and follow maps.org/safety for information regarding MAPS Code of Ethics for Psychedelic Psychotherapy and our practices to create a culture of safety in the psychedelic community. | maps.org
The FDA has rejected Lykos Therapeutics’ New Drug Application for MDMA-assisted therapy for PTSD and requested an additional Phase 3 study.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
As Lykos Therapeutics awaits an FDA decision this week on its proposed MDMA-assisted therapy for PTSD, the company has announced new initiatives and measures for additional oversight if the therapy is approved.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
Lykos Therapeutics addresses concerns from FDA Advisors about MDMA-assisted therapy and presents a forward looking plan.| Lucid News - Psychedelics, Consciousness Technology, and the Future of Wellness
